Klenowski, Paul M.
Zhao-Shea, Rubing
Freels, Timothy G.
Molas, Susanna
Tapper, Andrew R. http://orcid.org/0000-0002-8358-6937
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA041482, DA047678, DA041482, DA047678, DA041482, DA047678)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 29 January 2021
Revised: 12 July 2021
Accepted: 13 July 2021
First Online: 29 July 2021
Change Date: 26 August 2021
Change Type: Update
Change Details: The sentence in the abstract that reads "which inherently decrease IPN GABAergic neuron activity as a mechanism was corrected to "which inherently decrease IPN GABAergic neuron activity as a withdrawal-coping mechanism". In the results section, “Somatic behaviors reduce IPN GABAergic neuron activity during mecamylamine-precipitated withdrawal” the first sentence which reads “To test the effect of somatic withdrawal symptoms on IPN GABAergic neuronal activity,” was corrected to “To test the response of somatic withdrawal symptoms on IPN GABAergic neuronal activity.”